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BACKGROUND AND PURPOSE
Multicatalytic endopeptidase complex-like-1 (β2i), low molecular mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the pro-
teolytically active subunits of the immunoproteasome, a special type of proteasome mainly expressed in haematopoietic cells.
Targeting LMP7 has been shown to be therapeutically effective in preclinical models of autoimmune diseases. In this study, we
investigated the selectivity and biological activity of LU-005i, a recently described inhibitor of the immunoproteasome.
EXPERIMENTAL APPROACH
The speciﬁcity of LU-005i and other immunoproteasome-selective inhibitors was characterized using ﬂuorogenic peptide sub-
strates. The effect of proteasome inhibition on cytokine release was investigated in endotoxin-stimulated mouse splenocytes or
human peripheral blood mononuclear cells (PBMCs). The effect of proteasome inhibition on inﬂammatory bowel disease in the
dextran sulfate sodium (DSS)-induced colitis model was assessed by measuring weight loss and colon length.
KEY RESULTS
LU-005i is the ﬁrst human and mouse immunoproteasome-selective inhibitor that targets all three proteolytically active
immunoproteasome subunits. LU-005i inhibited cytokine secretion from endotoxin-stimulated mouse splenocytes or human
PBMCs. Furthermore, differentiation of naïve T helper cells to T helper 17 cells was impaired in the presence of LU-005i. Addi-
tionally, LU-005i ameliorated DSS-induced colitis.
CONCLUSION AND IMPLICATIONS
This study with a novel pan-immunoproteasome inhibitor substantiates that the immunoproteasome is a promising drug target
for the treatment of inﬂammatory diseases and that exclusive inhibition of LMP7 is not necessary for therapeutic effectiveness. Our
results will promote the design of new generations of immunoproteasome inhibitors with optimal therapeutic efﬁcacy for clinical
use in the treatment of autoimmunity and cancer.
Abbreviations
CD, cluster of differentiation; CP, constitutive proteasome; DAI, disease activity index; DSS, dextran sulfate sodium; EAE,
experimental autoimmune encephalomyelitis; IP, immunoproteasome; LMP, low molecular mass polypeptide; MECL-1,
multicatalytic endopeptidase complex-like-1; MHC, major histocompatibility complex; NEPHGE, non-equilibrium pH
gradient gel electrophoresis; PBMCs, peripheral blood mononuclear cells; TCR, T cell receptor; Th, T helper cell; UTY,
ubiquitously transcribed tetratricopeptide repeat gene, Y-linked
BJP British Journal ofPharmacology
British Journal of Pharmacology (2018) 175 38–52 38
DOI:10.1111/bph.14069 © 2017 The British Pharmacological Society
Introduction
The proteasome is the main protease in charge of generat-
ing ligands for major histocompatibility complex (MHC) I
presentation (Groettrup et al., 1996; Basler et al., 2009). It
has a barrel-shaped structure consisting of four rings, each
with seven subunits. The inner two rings consist of β-subunits
and bear the catalytically active subunits proteasome sub-
unit beta 6 (β1c), proteasome subunit beta 7 (β2c) and pro-
teasome subunit beta 5 (β5c) (Huber et al., 2012). In
haematopoietic cells and in cells stimulated with IFN-γ or
TNF-α, these proteolytically active subunits are replaced by
proteasome subunit beta 9 [β1i; low molecular mass
polypeptide (LMP)2], proteasome subunit 10 [β2i;
multicatalytic endopeptidase complex-like (MECL)-1] and
proteasome subunit beta 8 (β5i; LMP7) forming the
immunoproteasome (IP). The immunoproteasome is in-
volved in the generation of MHC-I ligands (Basler et al.,
2004; 2011; 2012; 2013; Kincaid et al., 2012), in T cell expan-
sion (Basler et al., 2006; Moebius et al., 2010), T helper cell dif-
ferentiation (Muchamuel et al., 2009; Kalim et al., 2012;
Basler et al., 2014; Vachharajani et al., 2017), in protection
from immunopathological damage in the brain (Kremer
et al., 2010; Mundt et al., 2016) and in autoimmune diseases
(Muchamuel et al., 2009; Basler et al., 2010, 2014, 2015; Zaiss
et al., 2011; Ichikawa et al., 2012; Nagayama et al., 2012; Liu
et al., 2017).
Immunoproteasome inhibition ameliorated disease
symptoms in different animal models of autoimmune
diseases, like rheumatoid arthritis, inﬂammatory bowel
disease, Hashimoto’s thyroiditis, systemic lupus erythemato-
sus, neuritis (Liu et al., 2017) and multiple sclerosis
(summarized in ref. Basler et al., 2015). Two major pathways
involved in disease development are affected by LMP7 inhibi-
tion, namely, cytokine secretion and T helper cell differentia-
tion. LMP7 inhibition of T cell receptor (TCR)-activated T
cells and endotoxin-stimulated human peripheral blood
mononuclear cells (PBMCs) ormouse splenocytes strongly re-
duced the secretion of numerous pro-inﬂammatory cytokines
(Muchamuel et al., 2009; Basler et al., 2010; 2011; 2012; 2014;
Ichikawa et al., 2012; Sula Karreci et al., 2016). Additionally,
LMP7 inhibition prevents the differentiation of naïve T
helper cells to polarized Th17 cells in vitro (Muchamuel
et al., 2009; Kalim et al., 2012; Liu et al., 2017). These ﬁndings
indicate that immunoproteasome is a valid therapeutic tar-
get for the treatment of autoimmune diseases. Neverthe-
less, except for one study (Sula Karreci et al., 2016), all
these results were based on studies with a single com-
pound: ONX 0914 (formerly named PR-957). Therefore,
it is essential to conﬁrm previous data with new com-
pounds and to investigate the therapeutic beneﬁt of si-
multaneously inhibiting all three active site subunits of
the immunoproteasome.
Recently, using a structure-based approach, new
immunoproteasome-selective compounds were identiﬁed
(de Bruin et al., 2014). In the present study, we characterized
the biological activity of a panel of these compounds. We
found that an inhibitor selective for all three catalytically
active subunits of the immunoproteasome (LU-005i) was able
to inhibit pro-inﬂammatory cytokine release from
LPS-stimulated mouse splenocytes and human PBMCs,
reduce T helper cell differentiation and ameliorate experi-
mental colitis.
Methods
Animals
C57BL/6 mice (H-2b) were originally purchased from Charles
River, Germany. LMP7 gene-targeted mice (Fehling et al.,
1994) were kindly provided by Dr John J. Monaco
(Department of Molecular Genetics, Cincinnati Medical
Centre, Cincinnati, OH, USA). Animal experiments were
approved by the Review Board of Regierungspräsidium
Freiburg in accordance with German Animal Protection
Law. The study went through a process of ethical review
(Regierungspräsidium Freiburg) prior to its commencement.
Animal studies are reported in compliance with the ARRIVE
guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015).
All the animals were housed in groups of three to ﬁve animals
in Eurotype II long clear-transparent plastic cages with
autoclaved dust-free sawdust bedding. They were fed a
pelleted and extruded mouse diet ad libitum and had unre-
stricted access to drinking water. The light/dark cycle in the
room consisted of 12/12 h with artiﬁcial light. Mice were kept
in a speciﬁc pathogen-free facility, and female mice were used
at 8–12 weeks of age, at a weight of 20–25 g. Mice were killed
by cervical dislocation or CO2 inhalation.
Cell lines and media
LCL721.174 cells [contain constitutive proteasome (CP)] and
LCL721.145 cells (contain immunoproteasome) (Salter and
Cresswell, 1986) were kindly provided by Hansjörg Schild
(Mainz University). All media were purchased from
Invitrogen-Life Technologies (Karlsruhe, Germany) and
contained GlutaMAX, 10% FCS and 100 U·mL1
penicillin/streptomycin.
Purification of 20S proteasome from mouse
organs and fluorogenic assays
The puriﬁcation of 20S proteasomes from the liver of
LMP7//MECL-1/ double deﬁcient mice (source of mouse
constitutive proteasome), from the liver of lymphocytic
choriomeningitis virus (LCMV)-infected (8 days post infec-
tion with 200 pfu LCMV-WE i.v.) BALB/c mice (source of
mouse immunoproteasome), LCL 721.174 cells (source of
human constitutive proteasome) or LCL 721.145 cells (source
of human immunoproteasome) as well as the analysis of their
subunit composition on two-dimensional non-equilibrium
pH gradient electrophoresis (NEPHGE)-SDS-PAGE was per-
formed as described previously (Basler and Groettrup, 2012).
Hydrolytic assays for proteasome activity were performed
using ﬂuorogenic substrates, as detailed previously (Basler
and Groettrup, 2012). Substrates were dissolved in DMSO
(10mM) and used at 12.5 μM (Ac-PAL-AMC; BostonBiochem)
or at 100 μM (Suc-LLVY-AMC, Bz-VRG-AMC, Z-LLE-βNA;
Bachem). IC50 values were determined using GraphPad Prism
Software (version 4.03).
To investigate the cell permeability of LU-005i,
LCL721.174 cells (contain CP) and LCL721.145 cells (contain
immunoproteasome) were treated with different inhibitor
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concentrations in PBS + 25 mM HEPES for 30 min at 37°C.
The cell permeable substrate MeoSuc-GLF-AMC (Bachem)
(in DMSO 10 mM) was added at 40 μM to the cells and incu-
bated at 37°C. The ﬂuorescence intensity in the wells con-
taining the cells was measured at an excitation wavelength
of 360 nm and emission wavelength of 465 nm (inﬁnite
M200 pro, TECAN).
LacZ assay
The LacZ assay was performed exactly as described previously
(Basler and Groettrup, 2013). Brieﬂy, 105 cells of the ubiqui-
tously transcribed tetratricopeptide repeat gene, Y-linked
(UTY)246–254-speciﬁc T cell hybridoma (donated by N. Shastri,
University of California, Berkeley, Berkeley, CA, USA) were co-
cultured with 1.5 × 106 stimulator cells in 96-well plates
overnight. The lacZ-based colour reaction was achieved and
measured, as described in detail previously (Basler et al., 2004).
Cytokine secretion assay
Splenocytes (106 per well) fromC57BL/6mice were incubated
with proteasome inhibitors or DMSO and stimulated with
plate bound anti-cluster of differentiation (CD) 3 (5 μg·mL1,
clone 145-2C11, eBioscience) and anti-CD28 (5 μg·mL1,
clone 37.51, eBioscience) antibodies or stimulated with
3 μg·mL1 LPS. After 20 h, IFN-γ or IL-6 in the supernatant
was determined by ELISA, according to the manufacturer’s
protocol (eBioscience). Human PBMCs from healthy volun-
teers were incubated with proteasome inhibitors or DMSO
at 37°C and stimulated with 3 μg·mL1 LPS (from E. coli
0111:B4) (Sigma). After 20 h, IL-23 and IL-6 levels in the su-
pernatant were determined by ELISA, according to the manu-
facturer’s protocol (eBioscience).
Proteasome immunoprecipitation
To determine the proteasomal activity in lysates with
the ﬂuorogenic substrate Ac-PAL-AMC (BostonBiochem),
LCL721.174 cells were incubated with 300 nM LU-001i or
DMSO overnight at 37°C. Immunoprecipitation was per-
formed as described previously (Basler and Groettrup, 2012).
Brieﬂy, after extensive washing, equal amounts of cells were
lysed and incubated with 3 μL of polyclonal rabbit anti-
mouse proteasome antibodies (Schwarz et al., 2000) and
50 μL protein A microbeads (μMACSProtein A microbeads;
Miltenyi Biotec) for 30 min on ice. The lysate was applied to
the μ column (Miltenyi Biotec), and the column was washed
ﬁve times. Then, 50 μL ﬂuorogenic peptide substrate (Ac-
PAL-AMC) was applied to the column at a concentration of
12.5 μM. The μ column was incubated at 37°C for 30 min. A
total of 100 μL lysis buffer was added, and the ﬂuorescence in-
tensity in the eluate was measured at an excitation wave-
length of 360 nm and emission wavelength of 465 nm
(inﬁnite M200 pro, TECAN).
MHC-I surface expression
Splenocytes from C57BL/6 or LMP7/ mice were incubated
overnight with various concentrations of LU-005i or LU-
001i or DMSO control. H-2Kb surface staining was performed
as described previously (Basler and Groettrup, 2007). Brieﬂy,
splenocytes were incubated with anti-mouse CD16/32 (clone
2.4G2) to block Fc-receptors and then stained for H-2Kb
(clone AF6-88.5, BD Biosciences) for 30 min. After two
washes, cells were acquired with the use of the Accuri C6 ﬂow
cytometer system (BD Biosciences). Lymphocytes were gated
based on forward scatter and side scatter, and the median H-
2Kb ﬂuorescence of gated lymphocytes was calculated.
Propidium iodide staining
Splenocytes from C57BL/6 mice were incubated with various
concentrations of LU-005i or DMSO control for 1 to 3 days.
Cells were stained with antibodies (all BioLegend) for
CD11c, CD11b, F4/80, CD4, CD8, CD19 and NK1.1. The via-
bility of these cells was assessed with propidium iodide (PI)
(eBioscience) using the BD FACSVerse™ ﬂow cytometer (BD
Biosciences).
Th17 cell differentiation
Magnetically puriﬁed CD4+ T cells (MACS; Miltenyi Biotech)
were stimulated (8 × 104 cells per well) with plate-bound anti-
bodies to CD3 (5 μg·mL1, clone 145-2C11, eBioscience) and
CD28 (5 mg·mL1, clone 37.51, eBioscience) in the presence
of 2.5 ng·mL1 TGF-β (Preprotech), 30 ng·mL1 IL-6
(eBioscience) and antibodies to IL-4 (10 μg·mL1;
eBioscience) and IFN-γ (10 μg·mL1; eBioscience) for 3 days.
Intracellular IL-17A expression was measured 4 h after expo-
sure to 50 ng·mL1 PMA (Sigma) and 500 ng·mL1
ionomycin (Sigma) in the presence of 10 mg·mL1 brefeldin
A (Sigma) by ﬂow cytometery (Accuri C6).
Induction of colitis
Oral administration of dextran sulfate sodium (DSS) in mice
has been widely used to study the mechanisms of colonic in-
ﬂammation and to evaluate the effect of any candidate drug
for inﬂammatory bowel disease. Additionally, this animal
model has been chosen to compare the new data with previ-
ous results with different proteasome inhibitors obtained in
this model (Basler et al., 2010; Schmidt et al., 2010). Mice were
randomly separated into three groups (vehicle, LU-005i and
LU-001i). Colitis was induced in 8 to 10-week-old mice by
adding 3% DSS (m.w. 36 000–50 000; MP Biomedicals, Solon,
OH, USA) to the drinking water, beginning at day 0 for 5 days;
thereafter, mice were given regular drinking water. The body
weight was measured daily throughout the experiment. Mice
were killed with CO2. A weight loss>25%was deﬁned as a hu-
mane endpoint, no animal reached the endpoint. Colitis se-
verity was scored by evaluating clinical disease activity
through daily observation of the following parameters:
weight loss (0: no weight loss or weight gain; 1: 5–10%weight
loss; 2: 10–15% weight loss; 3: 15–20% weight loss; 4: >20%
weight loss); stool consistency (0: normal and well formed;
2: very soft and unformed; 4: watery stool); and bleeding
stool score (0: normal colour stool; 2: reddish colour stool;
4: bloody stool). The disease activity index (DAI) was calcu-
lated based on the combined scores of weight loss, stool con-
sistency and bleeding ranging from 0 to 12.
Real-time RT-PCR
Real-time RT-PCR was used to quantify cytokine expression
levels in mouse colons. Total RNA was extracted from the
colon of mice using a NucleoSpinRNA II extraction kit
(MACHEREY-NAGEL, Dueren, Germany). One microgram
of total RNA was reverse transcribed using oligonucleotide
(dT) primers and the reverse transcription system
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(Promega, Madison, WI, USA). Quantitative PCR was per-
formed with the Toptical professional thermocyler instru-
ment (Analytic Jena), using the Biozym Blue S’Green
qPCR Kit (Biozym), with the following primers:
IL-1β-speciﬁc forward: 50-TTGACGGACCCCAAAAGATG-30;
IL-1β reverse primer: 50-AGAAGGTGCTCATGTCCTCA-30; TNF-
α–speciﬁc forward: 50-ATGAGCACAGAAAGCATGATC-30;
TNF- α reverse primer: 50-TACAGGCTTGTCACTCGAATT-30;
IL-17–speciﬁc forward: 50-CTCCAGAAGGCCCTCAGACTAC-
30; IL-17 reverse primer: 50-GCTTTCCCTCCGCATTGACAC
AG-30; IL-6-speciﬁc forward: TGGACAGGACTGAAAGACT
TG-30; IL-6 reverse primer: 50-CCAGCAGGTCAGCAAAGAA
CTTA-30; IFN-γ–speciﬁc forward: 50-ATGAAC GCTACACAC
TGCATC-30; and IFN-γ reverse primer: 50-CCATCCTTTTG
CCAGTTCCTC-30. Mouse hypoxanthineguanine phospho-
ribosyl transferase was used as a reference gene with the
following primers: 50-TGGACAGGACTGAAAGACTTG-30
(forward) and 50-CCA GCA GGT CAG CAA AGA ACT TA-30
(reverse). Data were analysed by ΔCT-method (2-ΔΔCT)
(Schmittgen and Livak, 2008).
Histology
Mouse colons were Swiss-rolled and ﬁxed in 10% formalin
followed by parafﬁn embedding. Tissue sections of 4 μmwere
stained with haematoxylin and eosin for pathological evalu-
ation in a blinded manner. Histology scores were assessed as
previously deﬁned by Horino et al. (2008) with slight modiﬁ-
cations. The score is based on three different parameters: in-
ﬂammation severity (0–3); extent of inﬂammation (0–3);
and crypt damage (0–4).
Data and statistical analysis
In the DSS-induced colitis animal experiment, a co-worker
blinded to the experimental protocol randomized animals
into groups. For all other experiments randomization is not
applicable. DAI was determined in a blinded manner. Histo-
logical scoring was performed in a blinded manner by two
people who were unaware of the sample group. All other ex-
periments were not subjected to blinding since they result
in values not inﬂuenced by personal bias. Groups which
contained ﬁve or more independent replicates were subjected
to statistical analysis. The data and statistical analysis comply
with the recommendations on experimental design and anal-
ysis in pharmacology (Curtis et al., 2015). ELISA and ﬂow cy-
tometry experiments were performed in triplicate to ensure
the reliability of singe values. Group sizes within an experi-
ment are equal, except for the naïve mice used in Figure 5.
This group was used as an illustrative control group, and
therefore, the group size was reduced so as not to unnecessar-
ily kill mice. The statistical signiﬁcance of the differences was
determined using either Student’s t-test or one-way ANOVA
with Dunnett’s multiple comparisons test. Dunnett’s multi-
ple comparisons test was run only if F achieved P < 0.05
and there was no signiﬁcant variance inhomogeneity as de-
termined with Bartlett’s test. All statistical analyses were per-
formed using GraphPad Prism Software (version 4.03)
(GraphPad, San Diego, CA, USA). A P value of <0.05 was con-
sidered signiﬁcant. If not indicated otherwise, differences are
not signiﬁcant. The number of mice for the colitis experi-
ment was determined using G*Power 3.0.10 (comparison of
two independent groups) (Faul et al., 2007).
Materials
Proteasome inhibitors LU-005i, LU-015i, LU-025i, LU-035i,
LU-045i, LU-055i and LU-001i were synthesized as described
previously (de Bruin et al., 2014). ONX 0914 (Muchamuel
et al., 2009) (formerly called PR-957) (Onyx Pharmaceuticals)
and other proteasome inhibitors were dissolved at a concen-
tration of 10 mM in DMSO and stored at 80°C (Muchamuel
et al., 2009). For proteasome inhibition in mice, LU-005i and
LU-001i were dissolved in 5% ethanol, 10% PEG 300 (Sigma)
in an aqueous solution of 20% (w. v-1) sulfobutylether-
ß-cyclodextrin and 10 mM sodium citrate (pH 6) and admin-
istered to mice s.c. (15 mg·kg1).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.
org, the common portal for data from the IUPHAR/BPS Guide
to PHARMACOLOGY (Southan et al., 2016), and are perma-
nently archived in the Concise Guide to PHARMACOLOGY
2017/18 (Alexander et al., 2017).
Results
Specificity of LU-005i, LU-015i, LU-025i,
LU-035i, LU-045i, LU-055i and LU-001i
Using a structure-based design approach, de Bruin et al.
(2014) obtained proteasome inhibitors with considerably
improved selectivity for β5i over β5c and β2i over β2c.
Out of these inhibitors, compounds LU-005i, LU-015i,
LU-025i, LU-035i, LU-045i, LU-055i and LU-001i were
chosen to conﬁrm the selectivity of these inhibitors with
puriﬁed proteasomes in ﬂuorogenic peptide assays.
Therefore, human constitutive proteasomes and human
immunoproteasomes were puriﬁed from the Epstein–Barr
virus-positive lymphoblastoid cell line LCL721.145
(source of immunoproteasome) and its LMP2- and LMP7-
deﬁcient deletion mutant LCL721.174 (source of CP) (Salter
and Cresswell, 1986). Purity and proteasome composition of
the 20S proteasomes from these cell lines was analysed by
NEPHGE-2D-gel electrophoresis (Supporting Information
Figure S1). Proteasomes derived from LCL721.174 cells
exclusively contain constitutive proteasomes, whereas
immunoproteasomes derived from LCL721.145 cells contain
approximately 10% constitutive subunits. Human CP and
immunoproteasome were incubated with different con-
centrations of LU-005i, LU-015i, LU-025i, LU-035i, LU-045i,
LU-055i and LU-001i and assayed with a ﬂuorogenic
substrate speciﬁc for the chymotrypsin-like activity of the
proteasome (Suc-LLVY-AMC). To compare the selectivity of
these proteasome inhibitors, the IC50 values were calculated
(Table 1). No inhibition of the chymotrypsin-like ac-
tivity for the LMP2-selective inhibitor LU-001i (de Bruin
et al., 2014) was observed, indicating that LU-001i did not in-
hibit β5c or β5i. LU-015i, LU-025i, LU-035i and LU-055i
showed IC50 values for the immunoproteasome of around
107 M whereas no inhibition of the CP below 106 M was ob-
served. LU-005i and LU-045i inhibited the chymotrypsin-like
activity of the immunoproteasome at IC50 values of around
107 M and were at least 10 times more selective for the
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immunoproteasome than for the CP. Although human and
murine proteasome subunits share more than 90% sequence
identity, small differences in the substrate binding pockets
can affect inhibitor binding (Huber et al., 2012). Therefore,
we tested whether compounds LU-005i, LU-015i, LU-025i,
LU-035i, LU-045i, LU-055i and LU-001i also inhibit mouse
20S proteasomes. Immunoproteasomes were isolated from
livers of BALB/c mice 8 days after infection with LCMV, and
constitutive proteasomes were puriﬁed from livers of unin-
fected LMP7//MECL-1/ gene-targeted mice (Khan et al.,
2001; Huber et al., 2012). After assessment of their purity by
two-dimensional gel electrophoresis as described previously
(Khan et al., 2001; Huber et al., 2012), mouse CPs and mouse
immunoproteasomes were incubated with different con-
centrations of LU-005i, LU-015i, LU-025i, LU-035i, LU-045i,
LU-055i and LU-001i and assayed for the chymotrypsin-like
activity (Table 1). No inhibition of the chymotrypsin-like ac-
tivity of mouse CP and immunoproteasome below 106 M
could be observed for LU-035i, LU-055i and LU-001i.
LU-015i, LU-025i and LU-045i showed IC50 values in the
μM range for mouse immunoproteasome and were therefore
at least 10 times less potent compared to human
immunoproteasome. In contrast, IC50 values of LU-005i for
mouse immunoproteasome and CP were comparable to hu-
man proteasome. To investigate the impact of the inhibitors
on the caspase-like activity, which is evoked by β1c, human
and mouse CPs were incubated with different inhibitor
concentrations and assayed with the ﬂuorogenic substrate
z-LLE-βNA (Table 1). None of the inhibitors tested reduced
the caspase-like activity below 106 M. Next, mouse and
human immunoproteasome were incubated with protea-
some inhibitors, and the trypsin-like activity was assessed
with the ﬂuorogenic substrate Bz-VGR-AMC (Table 1).
Apart from LU-005i, none of the inhibitors tested affected
the trypsin-like activity, indicating that these inhibitors
do not inhibit MECL-1, the proteolytically active subunit
in the immunoproteasome responsible for the trypsin-like
activity.
Since we intended to evaluate the potential of
immunoproteasome-selective inhibitors in the mouse system,
we further focused on LU-005i (Figure 1A). Additionally, LU-
001i, described as an LMP2-selective inhibitor, was further
characterized (Figure 1A). Ac-PAL-AMC is a ﬂuorescent sub-
strate exclusively cleaved by LMP2 (Blackburn et al., 2010;
Basler et al., 2012). Mouse and human immunoproteasomes
were incubated with different concentrations of LU-005i or
LU-001i and assayed with the ﬂuorogenic substrate speciﬁc
for LMP2 activity (Table 2). Both compounds were potent
LMP2 inhibitors. Lastly, the inhibition of the trypsin-like
activity of human and mouse CP was analysed (Table 3).
LU-001i did not affect the trypsin-like activity of either mouse
or human CP. In contrast to mouse CP, for which LU-005i
showed no inhibition below 106 M, LU-005i affected the
trypsin-like activity of human CP with IC50 values of
3.1 μM. Taken together, these ﬁndings indicate that LU-001i
(Figure 1A) is a potent mouse and human LMP2 inhibitor that
does not affect other catalytically active proteasome subunits
(Tables 1–3). LU-005i (Figure 1A) is an effective inhibitor of
MECL-1, LMP2 and LMP7 with at least 10-fold selectivity over
β2c, β1c and β5c and, therefore, can be considered as a general
immunoproteasome-selective inhibitor (Tables 1–3).Ta
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Next, we tested the cell permeability of LU-005i and
LU-001i cells. LCL721.174 (contain human CP) or
LCL721.145 (contain human IP) cells were incubated with
Figure 1
LU-005i reduces H-2Kb surface expression on splenocytes. (A) Structure of LU-005i (left side) or LU-001i (right side). (B, C) Flow cytometry analysis
of H-2Kb surface expression on splenocytes derived from C57BL/6 (left side) or LMP7/ (right side) mice treated with the indicated concentra-
tions of LU-005i (B) or LU-001i (C) overnight. Pooled data from ﬁve independent experiments performed in triplicates are shown as the means
of median ﬂuorescent intensity ± SEM. All data were statistically compared to the DMSO treated group. *P < 0.05.
Table 2
IC50 values of the indicated compounds were determined using the
hydrolysis of ﬂuorogenic substrates for LMP2-activity (PAL-AMC) of
20S immunoproteasomes of human or mouse origin
LU-005i LU-001i
Human IP 5.2 ± 2.9 108 M 1.6 ± 0.2 108 M
Mouse IP 2.0 ± 0.7 108 M 3.9 ± 1.2 109 M
IC50 values ± SD are indicated.
Table 3
IC50 values of the indicated compounds were determined using the
hydrolysis of ﬂuorogenic substrates for the trypsin-like activity
(VGR) of 20S immunoproteasomes or constitutive proteasomes de-
rived from humans or mice
LU-005i LU-001i
Human IP 4.7 ± 0.9 107 M n.i.
CP 3.1 ± 0.5 106 M n.i.
Mouse IP 1.8 ± 0.5 107 M n.i.
CP n.i. n.i.
IC50 values ± SD are indicated. n.i., no inhibition observed below
1 μM.
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different concentrations of LU-005i and assayed with the cell
permeable substrate MeO-Suc-GLF-AMC (Harding et al.,
1995) cleaved by the chymotrypsin-like activity of the pro-
teasome (Supporting Information Figure S2A). LU-005i
inhibited the cleavage of this substrate in cells containing
immunoproteasomes, demonstrating that LU-005i is cell per-
meable. Since the substrate to test LMP2-activity (Ac-PAL-
AMC) is poorly cell permeable, we tested the cell permeability
of LU-001i with a method based on immunoprecipitation.
LCL721.145 (contain IP) cells were incubated with 300 nM
LU-001i. After extensive washing, cells were lysed and the
proteasome was immunoprecipitated. The precipitated pro-
teasome was assayed for the cleavage of the LMP2-speciﬁc
substrate Ac-PAL-AMC (Supporting Information Figure S2B).
Whereas the substrate was converted by proteasomes from
untreated cells, proteasomes derived from cells incubated
with 300 nM LU-001i had strongly reduced activity, demon-
strating the cell permeability of LU-001i. To determine
whether complete inhibition of immunoproteasome induces
cell death, mouse splenocytes were incubated with different
concentrations of LU-005i. After 24, 48 and 72 h, CD11c+,
CD11b+, NK1.1+, CD19+, CD4+ and CD8+ populations were
analysed for cell death by PI staining (Supporting
Information Figure S3). Cell death of all populations in-
creased over time independently of LU-005i treatment.
Whereas at 24 h, no signiﬁcant effect of LU-005i on cell death
could be observed for all populations, a slight increase in the
death of CD4+ and CD8+ T cells at 500 and 1000 nM was ob-
served at 48 and 72 h. This is not surprising since the protea-
some is essential for cell survival and T cells mainly express
immunoproteasome.
LU-005i reduces the cell surface expression of
MHC class I
The cell surface expression of MHC-I is reduced in
LMP7-deﬁcient mice (Fehling et al., 1994). Therefore, we
compared the effect of LU-005i and LU-001i on MHC-I
H-2Kb surface expression in wild-type or LMP7-deﬁcient
splenocytes (Figure 1B, C). Based on the data obtained in
in vitro ﬂuorogenic assays (Tables 1–3), splenocytes were incu-
bated with different LU-001i and LU-005i concentrations
ranging from 50 to 1000 nM overnight: LU-005i reduced
the expression of H-2Kb in a dose-dependent manner,
whereas basal H-2Kb expression on LMP7/ splenocytes,
which is approximately 50% lower relative to wild-type
levels, was not further affected by LU-005i treatment
(Figure 1B). The LMP2-selective inhibitor LU-001i had no in-
ﬂuence on the cell surface expression of MHC-I (Figure 1C).
LU-005i affects the presentation of an
LMP7-dependent epitope
The generation of the cytotoxic T lymphocyte epitope
UTY246–254, derived from the endogenously expressed
Y-chromosome–encoded HY-Ag, has been shown to be
LMP7-dependent (Palmowski et al., 2006; Basler et al., 2012).
Furthermore, the presentation of the UTY246–254 epitope can
be reduced by an LMP7-selective, but not by an LMP2-
selective inhibitor (Muchamuel et al., 2009; Basler et al.,
2012). To conﬁrm these results with LU-005i and LU-001i,
UTY246–254 presentation on the H-2D
b class I molecule of
male-derived splenocytes was determined with a UTY246–254-
speciﬁc T cell hybridoma in lacZ assays (Figure 2). As reported
previously, the presentation of UTY246–254 was shown to be
dependent on LMP7 and could be reduced in a dose-
dependent manner with the immunoproteasome-selective
inhibitor LU-005i (Figure 2A). The LMP2-selective inhibitor
LU-001i had no inﬂuence on the presentation of the
UTY246–254 epitope (Figure 2B).
LU-005i inhibits cytokine secretion
It has previously been shown that a selective inhibitor of the
immunoproteasome subunit LMP7 blocks cytokine
Figure 2
LU-005i blocks MHC-I–restricted presentation of an LMP7-dependent epitope. Presentation of UTY246–254 on MHC-I by wild-type (WT)
splenocytes after exposure to the indicated concentrations of LU-005i (A) or LU-001i (B), as analysed by exposure to H-2Db-UTY246–254-speciﬁc,
LacZ-expressing T cell hybridomas. Female, LMP7-deﬁcient and ONX 0914 (300 nM) treated splenocytes were used as controls. Pooled data from
ﬁve independent experiments conducted in triplicates are shown as means ± SEM. All data were statistically compared to the WT male group.
*P < 0.05.
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production (Muchamuel et al., 2009; Basler et al., 2010, 2011;
2014). Therefore, splenocytes derived from wild-type or
LMP7-deﬁcient mice were incubated with different doses of
LU-005i and stimulated with LPS overnight. IL-6 in the super-
natant was detected by ELISA (Figure 3A). Whereas IL-6
secretion of wild-type splenocytes was reduced in a dose-
dependent manner by LU-005i, it had no inﬂuence on IL-6
secretion of LMP7-deﬁcient cells. LU-001i did not alter IL-6
secretion of LPS-stimulated wild-type splenocytes (Figure 3B).
Next, splenocytes derived from wild-type mice were treated
with LU-005i or LU-001i and stimulated with plate-bound
anti-CD3/anti-CD28 antibodies overnight. IFN-γ secretion
into the supernatant was determined by ELISA (Figure 3C). In
contrast to LU-001i, LU-005i reduced IFN-γ secretion into
the supernatant in a dose-dependent manner.
Next, we evaluated the impact of selective immunopro-
teasome inhibition on cytokine production of endotoxin-
stimulated human PBMCs. Human PBMCs from healthy
volunteers were exposed to LU-005i or LU-001i and
stimulated with LPS (Figure 3D, E). Compared to 300 nM
ONX 0914, LU-005i only slightly reduced IL-6 production at
300, 500 and 1000 nM (Figure 3D). In contrast, IL-23 secre-
tion was fully blocked at 300 nM (Figure 3E). LU-001i had
no effect on cytokine secretion, either of IL-6 or of IL-23
(Figure 3D, E).
LU-005i blocks Th17 differentiation
The importance of the IL-23/IL-17 axis in the pathogenesis of
autoimmunity is well established. LMP7 inhibition prevents
the differentiation of naïve T helper cells to polarized Th1 or
Th17 cells in vitro (Muchamuel et al., 2009; Kalim et al.,
2012). Therefore, we investigated the effect of LU-005i on
Th17 differentiation. Magnetically-sorted CD4+ T cells de-
rived from wild-type or LMP7-deﬁcient mice were cultured
in vitro under Th17 polarizing conditions in the presence of
different concentrations of LU-005i (Figure 4). LU-005i
inhibited the Th17 differentiation in a dose-dependent man-
ner (Figure 4A). This inhibition was still LMP7-selective, since
LU-005i did not affect Th17 differentiation in LMP7-deﬁcient
CD4+ cells (Figure 4B). Moreover, LU-001i was found to have
no effects on Th17 differentiation (Figure 4C).
LU-005i reduces the symptoms of DSS-induced
colitis
Immunoproteasome inhibition prevented the production of
cytokines driving Th17 generation (Figure 3; Muchamuel
et al., 2009; Basler et al., 2014) and IL-17 production in T cells
cultured in the presence of polarizing cytokines (Figure 4;
Muchamuel et al., 2009; Kalim et al., 2012). Therefore, we
investigated the impact of immunoproteasome inhibition
in DSS-induced colitis in C57BL/6 mice. To analyse whether
LU-005i and LU-001i were active in mice, C57BL/6 mice were
treated with 15 mg·kg1 LU-005i or 15 mg·kg1 LU-001i, or
vehicle. Two and 24 h post treatment, proteasomes were
immunoprecipitated from spleen lysates and assessed with a
ﬂuorogenic substrate speciﬁc for the chymotrypsin-like activ-
ity (Suc-LLVY-AMC) and a substrate speciﬁc for LMP2-
activity (Ac-PAL-AMC; Supporting Information Figure S4).
Both inhibitors showed activity in mice and, thus, were used
to study the effect of immunoproteasome inhibition on
colitis. DSS-induced colitis was induced by oral administra-
tion of 3% DSS in the drinking water for 5 days. Mice
were treated daily with LU-005i (15 mg·kg1), LU-001i
(15 mg·kg1) or vehicle. Body weight and disease acti-
vity index (DAI) of the mice were recorded for 9 days
(Figure 5A, B). Compared to vehicle treatment, the adminis-
tration of LU-005i led to a signiﬁcantly reduced weight loss
and DAI. Interestingly, although LMP2-deﬁcient mice are
protected from DSS-induced colitis (Fitzpatrick et al., 2006;
Basler et al., 2010), treatment of mice with the LMP2-selective
inhibitor LU-001i had no effect on weight loss. The induction
of colitis is associated with a reduced colon length in diseased
mice. To investigate whether the decreased body weight loss
in LU-005i-treated mice is accompanied by an altered
colon length, this parameter was measured in DSS-treated
mice on day 9 post induction (Figure 5C). Colon length
was reduced in DSS-treated wild-type mice by approxi-
mately 2 cm compared with untreated naive mice. The colon
of LU-005i-treated mice showed a slight reduction compared
to that of naïve mice, whereas length of the colon in the LU-
001i-treated mice was comparable to that of vehicle-treated
mice. Nevertheless, the colon length of LU-005i-treated
mice was signiﬁcantly increased compared with vehicle-
treated mice. Colitis is accompanied by the accumulation of
a variety of inﬂammatory cells and the release of several
soluble mediators of inﬂammation, such as cytokines.
To determine whether the inﬂammatory response is altered
in LU-001i- and LU-005i-treated mice with colitis, TNF-α,
IFN-γ, IL-1β, IL-6 and IL-17 expression was determined by
real-time RT-PCR in colon on day 9 after colitis induction
(Figure 5D). Compared to naïve mice, cytokines were up-
regulated in vehicle-treated mice. Cytokine levels in LU-
001i-treated mice were comparable to vehicle-treated mice,
whereas the expressions of TNF-α, IL-1β and IL-17 were
signiﬁcantly reduced in LU-005i-treated mice. Inﬂammation
severity (0–3), extent of inﬂammation (0–3) and crypt
damage (0–4) were graded semiquantitatively onmicroscopic
cross sections of the colon on day 9 post colitis induction
(Figure 5E, F). A massive inﬁltration of immune cells and a
high histological score could be observed in vehicle- or
LU-001i-treated mice. In contrast, LU-005i-treated mice had
only mild signs of inﬂammation and crypt damage. Taken
together, these ﬁnding indicate that LU-005i strongly attenu-
ates the development of DSS-induced colitis in mice.
Discussion
Different studies using preclinical mouse models have
demonstrated that the immunoproteasome is an attractive
target for the treatment of autoimmune diseases (summa-
rized in Basler et al., 2015). Nevertheless, most of these
studies were based on a single compound, ONX 0914, an
LMP7-selective peptide-ketoepoxide proteasome inhibitor
(Muchamuel et al., 2009). Although different selective
immunoproteasome inhibitors have been developed, they
have not been thoroughly tested in preclinical models.
The expectation that the immunoproteasome crystal struc-
ture reported in 2012 (Huber et al., 2012; Basler et al., 2015)
will promote the structure-guided design of new
immunoproteasome inhibitors was recently realized (de Bruin
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Figure 3
LU-005i inhibits the production of inﬂammatory cytokines. (A–C) Splenocytes derived from C57BL/6 (A–C) or LMP7/ (A) mice were exposed to
the indicated concentrations of LU-005i (A, C) or LU-001i (B, C) and stimulated with LPS (A, B) or plate-bound antibodies speciﬁc for CD3/CD28
(C) overnight. IL-6 (A, B) or IFN-γ (C) in the supernatant was analysed by ELISA. Each data point was measured in triplicates. The highest cytokine
concentration from each experiment was set to 100% to control for unwanted variations in cytokine secretion between individual experiments.
Data are presented as the mean ± SEM of six (A, B) or ﬁve (C) independent experiments. (D, E) Human PBMCs were exposed to the indicated con-
centrations of LU-005i (left side) or LU-001i (right side) and stimulated with LPS overnight. IL-6 (D) or IL-23 (E) in the supernatant was analysed by
ELISA. Each data point was measured in triplicates. The highest cytokine concentration from each experiment was set to 100% to control for un-
wanted variations between individual donors. Data are presented as the mean ± SEM of six (D) or eight (E) independent donors. All data were
statistically compared to the DMSO treated group. *P < 0.05.
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et al., 2014; Singh et al., 2016; Sula Karreci et al., 2016).
De Bruin et al. report the development of new β1i- and
β5i-selective inhibitors. Using known inhibitors as starting
points and introducing structural features according to the
X-ray structures of the murine constitutive and
immunoproteasome 20S core particles, these new inhibitors
are the result of a rational design strategy. Some of these inhib-
itors were further characterized with human and mouse
proteasomes in ﬂuorogenic assays in this study (Table 1).
These assays indicate that inhibitors selective for human
LMP7 are not naturally selective for mouse proteasomes. In-
deed, X-ray structures of humanized yeast proteasome iden-
tify unique binding modes of inhibitors for human β5i
(Huber et al., 2016). Although the substrate binding pockets
and the active site residues are highly conserved among mice
and humans, the residues outside the natural substrate bind-
ing channel, such as the S3* pocket identiﬁed, are subjected
to variances, thereby creating species-speciﬁc differences such
as Val/Met31 (Huber et al., 2016). Based on the activity in
the mouse proteasome, we decided to further investigate
two compounds, LU-005i and LU-001i, in more detail. In
vitro ﬂuorogenic assays with different substrates demon-
strated that LU-005i is over 10 times more selective for
MECL-1, LMP2 and LMP7 than β2c, β1c and β5c (Tables 1–3).
LU-001i was shown to be an LMP2-selective inhibitor
(Tables 1–3), conﬁrming previous results (de Bruin et al.,
2014). Hence, LU-005i is the ﬁrst proteasome inhibitor
described that simultaneously inhibits all three immuno-
proteasome subunits. Immunoproteasomes have been shown
to be involved in the generation of MHC-I ligands. This is
evident in cells derived from LMP7-deﬁcient mice, which
have an approximately 50% reduction in MHC-I surface
expression compared to wild-type cells (Fehling et al., 1994).
Since LMP7-deﬁcient mice also display a reduced LMP2 and
MECL-1 incorporation into immunoproteasomes, the altered
MHC-I surface expression observed in LMP7-deﬁcient mice
cannot be attributed to a single immunoproteasome subunit
(De et al., 2003). Treatment of splenocytes with LU-005i
reduced MHC-I surface expression only in wild-type cells but
not in LMP7-deﬁcient cells (Figure 1B), demonstrating that
LU-005i is immunoproteasome-selective. The LMP2-selective
inhibitor LU-001i did not alter class-I surface expression,
Figure 4
LU-005i blocks Th17 differentiation. Differentiation of CD4+ T cells from C57BL/6 (A, C) or LMP7/ (B) mice exposed to the indicated concen-
trations of LU-005i (A, B) or LU-001i (C) and stimulated with antibodies to CD3/CD28 in the presence of TGF-β and IL-6 and antibodies to IL-4
and IFN-γ was measured in 3 day cultures. IL-17 expression was detected by intracellular cytokine staining after a short restimulation with
PMA/ionomycin. IL-17 expression in activated T cells cultured in the absence of Th17-polarizing conditions is shown as a comparison (no cock-
tail). Pooled data from ﬁve independent experiments done in triplicates are shown as means ± SEM. Values reﬂect the percentage of CD4+ cells
that are also IL-17A+. All data were statistically compared to the DMSO-treated group. *P < 0.05. The ‘no cocktail’ group was excluded from sta-
tistical analysis due to variance inhomogeneity.
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indicating that LMP2 alone is not sufﬁcient to reduce
MHC-I surface expression.
Cytokines play crucial roles in the regulation of the
immune response. LU-005i treatment of endotoxin- or TCR-
stimulated mouse splenocytes strongly reduced IL-6 or IFN-γ
secretion in an immunoproteasome-dependent manner
(Figure 3). Whereas LU-005i was less potent at inhibiting
IL-6 production from LPS-stimulated human PBMCs, it
completely inhibited IL-23 secretion (Figure 3E). In line with
previous results (Muchamuel et al., 2009; Basler et al., 2014),
immunoproteasome inhibition in IL-23-producing cells,
probably monocytes, is extremely efﬁcient at preventing
IL-23 secretion. The reason why IL-23 secretion is strongly
affected by immunoproteasome inhibition remains to be
Figure 5
LU-005i ameliorates DSS-induced colitis. Colitis was induced by oral administration of 3% DSS for 5 days. Mice were treated daily (s.c.) with LU-
005i (15 mg·kg1), LU-001i (15 mg·kg1), or vehicle as indicated. All data were statistically compared to the vehicle-treated group. *P< 0.05. (A)
Body weight of individual mice was monitored daily: % weight loss (y-axis) is plotted versus time (x-axis). Data points represent mean ± SEM of 13
mice. (B) DAI was determined daily. Data points represent mean ± SEM of six mice. (C) On day 9, colon length was analysed. Naïve mice (n = 5)
were used as healthy controls. Data points represent mean ± SEM of 13 mice. (D) TNF-α, IL-1β, IL-6, IFN-γ and IL-17 mRNA content was analysed
by real-time RT-PCR in colon on day 9. The values were normalized to the expression of hypoxanthineguanine phosphoribosyl transferase in the
same organs, and the relative cytokine expression was calculated, with the value for lowest expression being arbitrarily set to unity. Data points
represent mean relative mRNA expression levels ± SEM of six mice or ﬁve mice (naïve group). The ‘naive’ group of IL-1β and IL-17 was excluded
from statistical analysis due to variance inhomogeneity. (E) Semiquantitative histopathological assessment of colitis on day 9. Data points repre-
sent mean histopathological score ± SEM of 12 mice or 4 mice (naïve group). The ‘naïve’ group was not statistically analysed due to the low num-
ber of mice used. (F) Representative histological colon sections of the indicated groups of mice (H&E, original magniﬁcation ×10). Scale bar
corresponds to 100 μm.
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investigated. Whereas IL-6 and IL-1β are necessary for the in-
duction of Th17 cells, IL-23 is responsible for the mainte-
nance of Th17 and for the production of IL-17 (Aggarwal
et al., 2003; Bettelli et al., 2006). Hence, immunoproteasome
inhibition is a promising strategy for reducing IL-23 secretion
and, therefore, suppressing Th17 development. Indeed,
in vitro Th17 differentiation was reduced with LU-005i-
treated T helper cells (Figure 4), conﬁrming previous observa-
tions, obtained both in vitro and in vivo (Muchamuel et al.,
2009; Schmidt et al., 2010; Kalim et al., 2012; Basler et al.,
2014; Vachharajani et al., 2017). Th17 cells are known to ex-
press high levels the multi-drug transporter MDR1 (also
known as P-glycoprotein and ABCB1), an ATP-dependent
membrane efﬂux pump with broad substrate speciﬁcity
(Ramesh et al., 2014). It has been shown that MDR1 can ex-
trude epoxyketone-peptide proteasome inhibitors such as
carfilzomib (CFZ/PR-171, trade name Kyprolis), ONX
0912 (PR-047) and ONX 0914 (Verbrugge et al., 2012).
Whether the epoxyketone-peptide proteasome inhibitors,
LU-001i or LU-005i, are affected by MDR1 remains to be de-
termined. It has been found that inhibiting the
immunoproteasome prevents the development of autoim-
mune diseases and of colitis-associated cancer (Koerner
et al., 2017; Vachharajani et al., 2017) in several preclinical
animal models (summarized in Basler et al., 2015). To eluci-
date the potency of LU-005i in vivo in an inﬂammatory dis-
ease, we chose to use the DSS-induced colitis model as a
proof of principle. Treatment of mice with LU-005i in this co-
litis model resulted in reduced body weight loss, DAI, colon
length shortening, cytokine expression in the colon and his-
tological scores compared to vehicle-treated mice (Figure 5).
Hence, as previously reported (Basler et al., 2010), targeting
the immunoproteasome in DSS-induced colitis ameliorates
the symptoms of this disease. In contrast, the inhibition of
LMP2 with LU-001i was not effective in this colitis model
(Figure 5). This ﬁnding conﬂicts with that obtained in
LMP2-deﬁcient mice, which were found to be partially
protected from DSS-induced colitis (Fitzpatrick et al., 2006;
Basler et al., 2010). Hence, it seems that the effects seen in
mice lacking LMP2 is based on a mechanism not relying on
the peptidolytic activity of LMP2. An opposite effect has been
shown in experimental autoimmune encephalomyelitis
(EAE). Although LMP7-deﬁcient mice were not protected
from EAE, LMP7 inhibition strongly reduced the clinical
symptoms of this disease (Nathan et al., 2013; Basler et al.,
2014). Interestingly, in LMP2- but not LMP7-deﬁcient mice
the development of thyroid oncocytes and primary hypothy-
roidism was ameliorated (Kimura et al., 2009). Furthermore,
pharmacological blockade of the proteasome with ML-273
prevented the development of the thyroid oncocytes in mice
expressingmurine IFN-γ speciﬁcally in thyroid follicular cells.
Since LMP7 inhibition is effective in an animal model of
Hashimoto’s thyroiditis (Nagayama et al., 2012) and the de-
velopment of thyroid oncocytes and primary hypothyroid-
ism is ameliorated in LMP2-deﬁcient mice (Kimura et al.,
2009), it would be interesting to determine whether LMP2 in-
hibition alone is also effective in these models. In our study,
we used LU-005i at 15 mg·kg1 in mice. Carﬁlzomib, which
is also a peptide-epoxyketone, when given to mice at a bolus
dose of 5 mg·kg1, was found to induce 80% inhibition of
chymotrypsin-like activity 1 h after application in adrenal,
heart, liver and whole blood (Demo et al., 2007). In humans,
carﬁlzomib is approved for treatment of multiple myeloma at
a dose of 20 mg·m2. Since carﬁlzomib achieves, in humans,
an 80% inhibition of ß5c and LMP7 activity in whole blood
and PBMCs at this dose (Lee et al., 2016), therapeutically ef-
fective doses of LU-005i should also be feasible in humans
to treat autoimmunity. Apart from autoimmune diseases,
the immunoproteasome has been shown to be involved in
other processes. LMP7 deﬁciency improves obesity and meta-
bolic disorders (Kimura et al., 2015), as LMP7 is involved in
regulating adipogenesis (Kitamura et al., 2011; Arimochi
et al., 2016), and the immunoproteasome is a regulator of
skeletal muscle differentiation (Cui et al., 2014). The dysregu-
lation of such processes leads to disorders which might po-
tentially be treated with immunoproteasome inhibitors.
Whether LU-005i or LU-001i is effective in the treatment of
metabolic disorders remains to be investigated.
The mechanism through which immunoproteasome in-
hibition can prevent autoimmune diseases still remains elu-
sive. It has been suggested that the immunoproteasome
might selectively process a factor that is required for regulat-
ing cytokine production and T helper cell differentiation
(Basler et al., 2013), but, so far, such a factor has not been
identiﬁed. The involvement of the immunoproteasome in
NF-kB activation has remained controversial (discussed in
Bitzer et al., 2017). Using a reporter cell line, Muchamuel
et al. (2009) showed no difference in NF-kB activation in
immunoproteasome-inhibited cells. However, it has recently
been reported that the mTORC1-immunoproteasome
pathway is important for cell survival against stress
(Yun et al., 2016). Whether this pathway is affected in
immunoproteasome-targeted mice in autoimmune diseases
remains to be determined.
Bortezomib, a proteasome inhibitor that reduces the ac-
tivities of CP and immunoproteasome, prevents chronic ac-
tive antibody-mediated rejection in experimental renal
transplantation in the rat (Vogelbacher et al., 2010). However,
the toxicological proﬁles of bortezomib suggest that protea-
some inhibitors with reduced toxicity need to be developed
for long-term treatment of transplant patients. Indeed, in a
recent study, Sula Karreci et al. (2016) describe a novel highly
selective LMP7 inhibitor named DPLG3. This non-covalent
inhibitor promoted long-term cardiac allograft acceptance
in mice across a major histocompatibility barrier. DPLG3 sup-
pressed the cytokine release from PBMCs and the activation
of T cells and dendritic cells. The numbers of effector T cells
in the allograft and draining lymph nodes were reduced,
while exhaustion markers on T cells were increased. Hence,
the inhibition of the immunoproteasome is a potential target
for the management of transplant rejection.
Taken together, our ﬁndings show that a new inhibitor
targeting all three catalytically active immunoproteasome
subunits is efﬁcient at preventing cytokine release, Th17 dif-
ferentiation and experimental colitis. Targeting the catalyti-
cally active immunoproteasome subunit LMP2 alone was
shown not to be effective. These results will be useful to guide
the design of new generations of immunoproteasome inhibi-
tors with optimal therapeutic efﬁcacy for the suppression of
autoimmunity and transplant rejection. This study conﬁrms
that the immunoproteasome is a clinically attractive target
in inﬂammatory diseases and that immunoproteasome
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inhibitors targeting all immunoproteasome subunits hold
potential clinical interest for the treatment of these diseases.
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Figure S1 Proteasome composition of LCL721.174 cells and
LCL721.145 cells. NEPHGE/SDS-PAGE analysis of 70 μg 20S
proteasome puriﬁed from LCL721.174 cells (CP) (top)
LCL721.145 cells (IP) (bottom). The proteins were visualized
by coomassie stain. The positions of proteasome subunits
LMP2, LMP7, β1c, and β5c are indicated.
Figure S2 Cell permeability of LU-005i and LU-001i. (A)
LCL721.174 cells (CP) or LCL721.145 cells (IP) were treated
with the indicated concentrations of LU-005i. The chymo-
trypsin-like activity in the cells was determined by the hydro-
lysis of the cell permeable substrate Meo-Suc-GLF-AMC.
Depicted is the mean ± SD % of maximal activity of triplicate
cultures. The highest ﬂuorescence value was set to 100%. (B)
LCL721.145 (contain IP) cells were incubated with 300 nM
LU-001i or DMSO overnight. Proteasomes of crude lysates of
these cells were immunoprecipitated and assayed for the hy-
drolysis of the ﬂuorogenic substrate Ac-PAL-AMC (LMP2-ac-
tivity). Depicted is the mean ± SD % of maximal activity of
triplicate cultures. The highest ﬂuorescence value was set to
100%. Experiments were performed twice with a similar out-
come. These experiments were only performed to demon-
strate the cell permeability of LU-005i and LU-001i.
Therefore, the data were not statistically analysed.
Figure S3 Effect of LU-005i on cell death. Splenocytes de-
rived from C57BL/6 mice were treated with DMSO, 300 nM
LU-005i, 500 nM LU-005i, or 1000 nM LU-005i for 24 h (A),
48 h (B), or 72 h (C). Cell death (PI+) of CD11c+, CD11b+,
F4/80+, CD19+, NK1.1+, CD4+, and CD8+ was analysed by
ﬂow cytometry. Shown are the means of PI+ populations ±
SEM from splenocytes derived from 5 different mice (n = 5).
All data were statistically compared to the DMSO treated
group. *P < 0.05.
Figure S4 Activity of LU-005i and LU-001i in mice. C57BL/6
mice were treated with LU-005i (A, B) (15 mg kg1), LU-001i
(C) (15 mg kg1), or vehicle for 2 h or 24 h. Proteasomes of
crude lysates of splenocytes derived from these mice were
immunoprecipitated and assayed for the hydrolysis of the
ﬂuorogenic substrate Ac-PAL-AMC (LMP2-acitivity) (A, C) or
Suc-LLVY-AMC (chymotrypsin-like activity) (B). Depicted is
the mean ± SD of the ﬂuorescence of twomice per groupmea-
sured in duplicates. Experiments were performed twice with a
similar outcome. These experiments were only performed to
demonstrate the activity of LU-005i and LU-001i in mice.
Therefore, the data were not statistically analysed.
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